Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Teniposide. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teniposide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teniposide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Teniposide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teniposide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Teniposide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Teniposide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teniposide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teniposide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teniposide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Teniposide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Teniposide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Teniposide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Teniposide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teniposide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Teniposide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Teniposide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teniposide. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teniposide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teniposide. |
| Cladribine | Teniposide may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Teniposide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Teniposide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Teniposide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Teniposide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Teniposide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Teniposide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Teniposide. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Teniposide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Teniposide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teniposide. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Teniposide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Teniposide. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Teniposide is combined with Epirubicin. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Teniposide is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Teniposide is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Teniposide is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Teniposide is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Teniposide is combined with Oxaliplatin. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Teniposide is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Teniposide is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Teniposide is combined with Pentostatin. |
| Linezolid | The risk or severity of adverse effects can be increased when Teniposide is combined with Linezolid. |
| Clofarabine | The risk or severity of adverse effects can be increased when Teniposide is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Teniposide is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Teniposide is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Teniposide is combined with Fludrocortisone. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Teniposide is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Teniposide is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Teniposide is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Teniposide is combined with Penicillamine. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Teniposide is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Teniposide is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Teniposide is combined with Carboplatin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Teniposide is combined with Dactinomycin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Teniposide is combined with Azathioprine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Teniposide is combined with Hydroxyurea. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Teniposide is combined with Mycophenolic acid. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Teniposide is combined with Mercaptopurine. |
| Thalidomide | The metabolism of Teniposide can be increased when combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Teniposide is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Teniposide is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Teniposide is combined with Flucytosine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Teniposide is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Teniposide is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Teniposide is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Teniposide is combined with Estramustine. |
| Lomustine | The risk or severity of adverse effects can be increased when Teniposide is combined with Lomustine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Teniposide is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Teniposide is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Teniposide is combined with Nelarabine. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Teniposide is combined with Ciclesonide. |
| Stepronin | The risk or severity of adverse effects can be increased when Teniposide is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Teniposide is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Teniposide is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Teniposide is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Teniposide is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Teniposide is combined with Brequinar. |
| Aldosterone | The risk or severity of adverse effects can be increased when Teniposide is combined with Aldosterone. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Teniposide is combined with Pirfenidone. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Teniposide is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Teniposide is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Teniposide is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Teniposide is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Teniposide is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Teniposide is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Teniposide is combined with Belatacept. |
| Bendamustine | The risk or severity of adverse effects can be increased when Teniposide is combined with Bendamustine. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Teniposide is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Teniposide is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Teniposide is combined with Eribulin. |
| Belimumab | The risk or severity of adverse effects can be increased when Teniposide is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teniposide is combined with Teriflunomide. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Teniposide is combined with Carfilzomib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Teniposide is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Teniposide is combined with Obinutuzumab. |